London, March 31, 2025 — Isomorphic Labs, a pioneering AI-first drug discovery company, has raised $600 million in its first external funding round. The round was led by Thrive Capital, with participation from GV (formerly Google Ventures) and continued support from Alphabet, the company’s founding backer.

This substantial investment underscores growing confidence in AI-driven biomedical research and marks a significant milestone in the industry’s shift toward computational drug development. Isomorphic Labs aims to revolutionize the drug discovery pipeline using its next-generation AI platform, which integrates powerful models such as AlphaFold 3, co-developed with Google DeepMind.

A New Era for Drug Design

Founded in 2021 and helmed by Sir Demis Hassabis, a leading figure in artificial intelligence and co-founder of DeepMind, Isomorphic Labs is on a mission to “solve all disease” by harnessing the potential of AI. The company’s platform utilizes advanced AI models to design drugs across multiple therapeutic areas and modalities, with an emphasis on oncology and immunology.

Notably, the company has already forged strategic collaborations with pharmaceutical giants Eli Lilly and Novartis. The latter recently expanded its partnership with Isomorphic Labs after a successful first year of collaboration.

AlphaFold 3, one of Isomorphic Labs’ flagship innovations, represents a leap in molecular modeling. Unveiled in May 2024, the model can predict the structure and interactions of virtually all molecules in the human body, enabling unprecedented insights into disease mechanisms and therapeutic targets.

What the Investors Are Saying

“We believe Isomorphic has earned a rare position to define a new age of drug discovery and design,” said Joshua Kushner, CEO of Thrive Capital. “We are deeply inspired by their mission and the extraordinary progress they have made to date.”

Dr. Krishna Yeshwant, Managing Partner at GV, added:

“After witnessing the extraordinary pace of innovation at Isomorphic Labs, we believe their pioneering approach will redefine AI-powered drug discovery. With Sir Demis Hassabis at the helm, Isomorphic has assembled an exceptional team at the intersection of life sciences and technology.”

Scaling Innovation and Talent

The $600 million injection will power the continued development of Isomorphic Labs’ AI drug design engine and help bring its pipeline of drug candidates into clinical development. It will also allow the company to expand its team of world-class scientists and technologists across its offices in London and Lausanne, Switzerland.

As the global pharmaceutical industry grapples with rising R&D costs and long development timelines, Isomorphic Labs represents a promising alternative: a scalable, AI-driven approach that could dramatically accelerate drug discovery while reducing failures in the clinic.

Looking Ahead

Isomorphic Labs stands at the intersection of biology, chemistry, and machine learning. With its unified AI platform and strong partnerships, the company is uniquely positioned to lead a new generation of biotech firms—those built from the ground up with artificial intelligence at their core.

For more on their mission and innovations, visit www.isomorphiclabs.com